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ORIGINAL ARTICLE

Primary Meningeal Pleomorphic Xanthoastrocytoma With
Anaplastic Features: A Report of 2 Cases, One With BRAFV600E
Mutation and Clinical Response to the BRAF Inhibitor Dabrafenib
Aisulu Usubalieva, MS, Christopher R. Pierson, MD, PhD, Christina A. Kavran, DO,
Kristin Huntoon, PhD, DO, Oleksandr N. Kryvenko, MD, Theodore G. Mayer, MD,
Weiqiang Zhao, MD, PhD, Jack Rock, MD, Mario Ammirati, MD, MBA,
Vinay K. Puduvalli, MD, and Norman L. Lehman, MD, PhD
Abstract
Primary meningeal gliomas are rare tumors composed of a heterogeneous group of neoplasms. We present 2 clinically aggressive cases of
primary meningeal pleomorphic xanthoastrocytoma that clinically
mimicked meningioma. One case presented in the posterior fossa of a
56-year-old woman; the other centered on the left operculum of a
35-year-old woman. These cases showed many of the classic features
of pleomorphic xanthoastrocytoma, except that xanthomatous cells
were rare and eosinophilic granular bodies were inconspicuous. Both
cases exhibited high proliferative indices and superficially invaded
the brain. One case harboring a BRAFV600E mutation disseminated to
the thecal sac and showed a clinical response to the targeted BRAF inhibitor dabrafenib. These cases seem to represent an unusual primarily
extra-axial presentation of pleomorphic xanthoastrocytoma and may
account for at least some of the previously reported cases of primary
meningeal glioma and/or glial fibrillary acidic protein–immunoreactive
meningioma variants. We suggest that BRAF mutation analysis be considered in all meningeal lesions showing atypical histologic or immunohistochemical profiles, particularly those exhibiting glial differentiation,
as a diagnostic aid and possible indication for targeted therapy.
Key Words: Anaplastic features, BRAFV600E, Extra-axial, High mitotic
rate, High proliferation index, Meningeal, Pleomorphic xanthoastrocytoma.

INTRODUCTION
Pleomorphic xanthoastrocytoma (PXA) is an uncommon
tumor that was first described as a unique entity in 1979 (1). It
most often arises in children and young adults and usually has
a predominant—often nodular and cystic—intra-axial component, which occurs superficially in the cerebral hemispheres.
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It also frequently involves the leptomeninges and occasionally
disseminates within the subarachnoid space (1–4). Most PXAs
are considered World Health Organization Grade II tumors,
which demonstrate low proliferative indices; however, some
transform into more aggressive lesions when they recur after resection. Examples presenting with mitotic rates greater than
5 per 10 high-power fields and/or necrosis are designated as
“pleomorphic xanthoastrocytoma with anaplastic features” by
the current World Health Organization classification scheme
and generally recur earlier (4, 5).
We present 2 cases of primary meningeal PXA. Both
cases occurred in adult women and showed high proliferative
indices and aggressive clinical courses. One case harbored a
BRAFV600E mutation. These rare tumors expand both the differential diagnosis of primary meningeal tumors and the list of tumors that should be tested for BRAF mutation.

MATERIALS AND METHODS
Immunohistochemistry
Formalin-fixed paraffin-embedded tissue was cut into
4-μm-thick sections and placed on positively charged slides
that were baked at 60°C for 1 hour, cooled, deparaffinized
and rehydrated through xylene and graded ethanol to water.
Slides were hematoxylin and eosin (H&E) or reticulin
stained, or immunohistochemically stained with antibodies to
CD34 (QBEnd/10 Cell Marque [Sigma, St Louis, MO], 1:400,
30-minute incubation), CD56 (1B6 [Novocastra, Buffalo Grove,
IL], 1:100, 30-minute incubation), desmin (D33 [Dako, Carpinteria,
CA], 1:200, 30-minute incubation), epithelial membrane antigen (EMA; E29 [Dako], 1:700, 30-minute incubation), glial fibrillary acidic protein (GFAP; rabbit polyclonal [Dako], 1:20000,
15-minute incubation), Ki-67 (MIB-1 [Dako], 1:400, 15-minute
incubation), Olig2 (rabbit polyclonal [IBL], 1:200, 15-minute incubation), pan-cytokeratin (AE1/AE3 [Dako], 1:300, 15-minute
incubation), progesterone receptor (pgR636 [Dako], 1:600,
30-minute incubation), S100 protein (rabbit polyclonal [Dako],
1:6000, 30-minute incubation), neurofilament protein (2F11
[Dako], 1:2000, 15-minute incubation), NeuN (A60 [Millipore,
Billerica, MA], 1:2000, 15-minute incubation) or vimentin
(V9 [Dako], 1:1800, 30-minute incubation). For all antibodies,
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except anti-S100 protein, heat-induced epitope retrieval was
performed with a Bond Autostainer Immunostaining System
(Leica Biosystems, Buffalo Grove, IL), using either a low-pH
or a high-pH retrieval solution (Bond Epitope Retrieval Solutions 1 and 2; Leica Biosystems). The sections were blocked
for endogenous peroxidase with a 3% hydrogen peroxide solution, incubated with the primary antibody for either 15 or
30 minutes, and subjected to a polymer-based detection system (Bond Polymer Refine Detection Kit; Leica Biosystems)
and counterstaining with hematoxylin. For S100 protein, antigen retrieval was performed using a vegetable steamer (95°C–
99°C) and a citric acid solution (pH 6.1) (Dako). After antigen
retrieval, blocking for endogenous peroxidase, and antibody incubation, polymer-based detection for S100 was performed on
the Bond Autostainer Immunostaining System. All slides were
dehydrated through graded ethanol to xylene and coverslipped.
Appropriate positive and negative controls were performed.
The mean Ki-67 labeling index was calculated from the percentage of positive cells in 10 consecutive nonoverlapping highpower fields (400).

BRAFV600E Mutation Analysis
BRAFV600E somatic mutation analysis was performed
using a single nucleotide extension assay (SNaPshot Multiplex
System; Life Technologies, Grand Island, NY). Results were
confirmed with Sanger sequencing.

Case 1
A 56-year-old woman presented with nausea, vomiting,
and imbalance for 10 days. Her medical history was significant
for a pituitary tumor that was followed up for many years. There
was no history of radiation therapy. Magnetic resonance (MR)
imaging confirmed a stable unchanged pituitary tumor and additionally showed a well-demarcated extra-axial mass lesion
(2.6 cm  2.0 cm) situated along the inferior medial aspect of
the left tentorial leaf, demonstrating a dural tail and compressing
the brainstem (Figs. 1A–D). The tumor was hypointense on
T1-weighted MR images, isointense on T2-weighted MR images,
and heterogeneously enhanced. Infratentorial meningioma was
favored clinically and radiologically. A ventriculoperitoneal shunt
was placed to resolve obstructive hydrocephalus, and the tumor
was subjected to gross total resection (Fig. 1E).
The patient experienced deteriorating mental status, and
follow-up neuroimaging 4 months after surgery showed an enlarging, enhancing, nodular lesion along the posterior and left
lateral sides of the midbrain and pons within the original tumor
bed, which also seemed to invade the temporal lobe (Fig. 1F). A
cytologic examination revealed no neoplastic cells in the cerebrospinal fluid. The patient subsequently underwent focal stereotactic radiosurgery of contrast-enhanced target in the left
brainstem and temporal lobe (16 Gy to the 90% isodose line).
She recovered, was doing well on the last follow-up 15 months
after surgery, and was alive 37 months after surgery.

Histopathology of Case 1
Hematoxylin and eosin–stained sections of the resection
specimen revealed a pleomorphic malignant tumor (Figs. 2A–F).
The bulk of the tumor was characterized by mild to moderately
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pleomorphic cells arranged in a variable fascicular pattern
(Figs. 2A–F). Many cells within these areas had oval nuclei with
delicate chromatin, occasionally with pseudoinclusions and moderate amounts of amphophilic cytoplasm with indistinct cell
borders mimicking meningioma (Figs. 2B–C). Despite the
overall lower-grade appearance of these regions, there were occasional intermixed anaplastic nuclei and mitotic figures (Fig. 2D).
In more pleomorphic areas close to the tumor interface
with the brainstem, the nuclei were irregular, with frequent large
atypical bizarre forms (Figs. 2E, F). They had coarse, irregularly
distributed chromatin and occasional nuclear vacuoles or prominent nucleoli. Up to 12 mitotic figures were counted in 10 highpower fields. Scattered, mostly perivascular lymphocytic
infiltrates were also noted. No definite microvascular proliferation or necrosis was seen. Typical large xanthomatous cells of
PXA and conspicuous eosinophilic granular bodies (EGBs)
were also not evident.
Reticulin stain was diffusely positive with less dense or
absent staining in the more pleomorphic areas (Fig. 2G). Much
of the tumor was immunopositive for GFAP (Fig. 2H), S100
protein (Fig. 2I), neural cell adhesion molecule (CD56), and
Olig2 (Fig. 2J). Focal CD34 immunopositivity and NeuN immunopositivity were noted (Fig. 2K). There was no immunoreactivity for desmin, EMA (Fig. 2L), or pan-cytokeratin (AE1/
AE3). The mean Ki-67 labeling index was 11% and varied from
5% in lower-grade areas to 20% in high-grade regions (Fig. 2M).
The tumor extended into the Virchow-Robin space with singlecell invasion into the brainstem (Figs. 2N, O). BRAFV600E mutation analysis yielded negative results.

Case 2
A 35-year-old woman presented with worsening headaches for 6 months. Magnetic resonance imaging showed a primarily extra-axial 2.5-cm lesion involving the left posterior
frontal-temporal operculum and overlying dura (Figs. 3A, B).
Near-total resection was achieved (Fig. 3C). Postoperatively,
she received external beam radiotherapy with 6-MV photons
to deliver 5,600 cGy focally to the resection site across 28 treatments. Follow-up imaging 5 months later showed a 3.6-cm irregular enhancement involving the left temporal lobe in the
region of prior surgery. The differential diagnosis was recurrence versus radiation-induced changes, and the patient was
followed up with serial imaging. The tumor progressed, showing enhancement along adjacent sulci, the sylvian fissure, and
the anterior aspect of the falx cerebri. Fifteen months after the
initial surgery, the patient underwent a second resection, now revealing a definite intra-axial component. She received fractionated stereotactic radiotherapy consisting of 5 fractions of 6-MV
photons delivering 600 cGy to the left temporal-parietal brain
for a total cumulative dose of 3,000 cGy.
Three months later, she presented with altered mental status, dilated pupils, and gait disturbance. Imaging showed enlargement of the ventricular system and patchy leptomeningeal
enhancement of the cord and cauda equina. Serial lumbar punctures yielded negative results for malignant cells. An intraventricular drain was placed to alleviate communicating hydrocephalus,
and the patient improved. Two months later, she further deteriorated, presenting with severe encephalopathy, status epilepticus,
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FIGURE 1. Case 1 neuroimaging. Preoperative sagittal T1-weighted (A), postcontrast T1-weighted coronal (B), and postcontrast T1weighted axial (C) MR images demonstrate a left infratentorial tumor. Arrows indicate the tumor in (A). Note tumor protrusion into the
posterior fossa and compression of the brainstem. Attachment to the inferior aspect of the tentorium and dural tail (arrow) is evident in
(C). (D) Preoperative fluid-attenuated inversion recovery image demonstrates tumor and edema in the pons and cerebellum. (E)
Postoperative T1-weighted MR image with contrast demonstrates surgery-related changes and absence of tumor. The coexisting
pituitary tumor is also enhanced. (F) Postoperative T1-weighted MR image with contrast demonstrates an enhancing recurrent
tumor in the tegmental pons and middle portion of the temporal lobe. Some delayed postoperative changes are also present.

and quadriparesis, and required ventilator support. Imaging showed
increased leptomeningeal enhancement now involving the entire spinal cord and cauda equina (Fig. 3D). Serial lumbar punctures again yielded negative results for malignant cells. A
biopsy specimen of leptomeningeal lesions in the lumbar region
was obtained.
The patient was treated with the targeted BRAF inhibitor
dabrafenib (150 mg twice daily; GlaxoSmithKline Pharmaceuticals, Philadelphia, PA). She showed significant improvements
in neurologic status, including cessation of seizures, and recovery of mental status, upper-limb strength, and respiration. Neuroimaging showed reduced subarachnoid disease in the brain
cisterns and around the brainstem and cervical and thoracic spinal cord. Unfortunately, 3 months after chemotherapy was initiated, the patient experienced a fall and suffered an intracranial
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hemorrhage in the prior tumor cavity. Dabrafenib therapy had
to be held for approximately 2 weeks. Subsequently, imaging
showed progression of her disease. The patient again experienced altered mental status and quadriplegia. Imaging showed
pneumocephalus and concern for brain abscess. She was taken
back to the operating room for evacuation of abscess/hematoma
and the recurrent tumor, was placed in hospice care, and died 3
1/2 weeks later (26 months after presentation).

Histopathology of Case 2
Hematoxylin and eosin–stained sections showed a neoplasm composed of spindle to epithelioid cells with occasional
fascicular arrangement (Fig. 4A). A few regions of the tumor
close to the brain surface demonstrated cells with large vacuolated
© 2015 American Association of Neuropathologists, Inc.
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FIGURE 2. Histologic findings in Case 1. (A) Low-power photomicrograph of tumor (H&E stain). (B–D) Areas reminiscent of
meningioma demonstrate mostly mildly pleomorphic oval nuclei with occasional larger atypical nuclei and mitotic figures (arrow in
D) (H&E stain). (E, F) More pleomorphic region of the tumor located closer to the brainstem surface (H&E stain). More numerous
bizarre tumor nuclei and mitotic figures are present in a vacuolated tumor background. (G) Reticulin fibers surround tumor cells in
the less pleomorphic areas but are absent in highly pleomorphic areas. (H) Glial fibrillary acidic protein immunostaining is diffusely
positive. There is a collection of lymphocytes in the center of the image. Immunohistochemical staining for S100 protein (I) and
Olig2 (J) yielded diffusely positive results. (K) A focal area of NeuN-immunoreactive tumor cells. (L) Epithelial membrane antigen
immunohistochemical staining yielded negative results. (M) The Ki-67 labeling index reached 20%. (N) Tumor-brainstem interface.
Tumor is present in the Virchow-Robin space on the left among myelinated fibers. Tumor cells invade the brainstem parenchyma on
the right. (O) Neurofilament (NF) immunostain demonstrates tumor cells infiltrating NF-positive axonal tracts at the tumorbrainstem interface. Original magnification: (A) 200, (B) 400, (C) 600, (D) 600, (E) 200, (F) 400, (G) 200, (H) 200,
(I) 100, (J) 200, (K) 400, (L) 200, (M) 400, (N) 200, (O) 400.
© 2015 American Association of Neuropathologists, Inc.
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FIGURE 3. Case 2 neuroimaging. (A) Preoperative axial postcontrast T1-weighted MR image of the extra-axial posterior frontal tumor.
(B) Postcontrast T1-weighted coronal MR image of the lesion demonstrating enhancing dural tails. Tumor is present on the operculum
but does not involve the underlying deep cortex of the lateral fissure (arrow). (C) Postoperative axial postcontrast T1-weighted MR
image demonstrates near-total resection and residual enhancement. (D) Magnetic resonance image shows spinal dissemination. (E)
Recurrent intracranial tumor with both intra-axial and exophytic components with hemorrhage.

pleomorphic nuclei (Fig. 4B). Rare xanthomatous cells were
noted (Fig. 4C). Rare gemistocyte-shaped cells were also present. Some of the latter appeared to have vague intracytoplasmic
inclusions, similar to rhabdoid cells (Fig. 4C). Scattered pale
round structures were noted, but definite EGBs were not
identified.
A focal collection of heterogeneous, irregularly shaped
calcifications—consistent with those found in gliomas—was
present in the less pleomorphic area of the tumor. The tumor
also showed scattered lymphocytic infiltrates, occasional apoptotic bodies, and up to 15 mitotic figures in 10 high-power
fields. Necrosis and vascular proliferation were absent.
Reticulin stain showed widespread positivity; many tumor
cells were completely enveloped by reticulin fibers (Fig. 4D).
There were some areas with only occasional intermixed GFAPimmunoreactive cells, but much of the tumor was diffusely
GFAP-positive (Fig. 4E). Tumor cells were also diffusely S100
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protein– and Olig2-immunopositive (Figs. 4F, G). Synaptophysin
and CD34 highlighted elongated cells in tumor fascicles (Figs. 4H,
I). Immunostains for EMA (Fig. 4K), desmin, AE1/AE3, and progesterone receptor yielded negative results. Antivimentin strongly
highlighted tumor cells but not cytoplasmic inclusions. The
mean Ki-67 labeling index was 15.5%, ranging from 4% to
33% (Fig. 4L).
A single well-formed psammoma body was present within
an entrapped meningothelial nest near the deep portion of the tumor adjacent to the brain surface (Fig. 4M). The tumor was adherent to and invaded the dura in tongue-like projections and as
single cells (highlighted by GFAP stain) (Fig. 4E). It also showed
extension into the brain surface via the Virchow-Robin space
(Fig. 4N); percolating single cells also invaded the cortical parenchyma (Fig. 4O).
Unlike the original resection, the intracranial recurrence
showed only typical PXA histology, including conspicuous
© 2015 American Association of Neuropathologists, Inc.
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FIGURE 4. Histologic findings in Case 2. (A) Low-power photomicrograph of a primary extra-axial tumor showing meningioma-like
appearance and partial fascicular growth pattern (H&E stain). (B) A more pleomorphic region of the tumor near the surface of the
brain (H&E stain). (C) High-power photomicrograph showing a rare xanthomatous giant cell (H&E stain). Rhabdoid-like cells were
also focally present (inset). (D) Reticulin stain shows positive staining of fibers that completely envelop tumor cells. (E) Glial fibrillary
acidic protein immunostain shows GFAP-positive tumor invading the dura (top) in a tongue-like fashion and via single-cell invasion
of spindle tumor cells (inset). (F) The tumor shows diffuse immunopositivity for S100 protein. Note the sarcoma-like fascicular
arrangement often observed in PXAs. (G) Immunostain for Olig2 shows widespread positivity. (H) Synaptophysin immunostain was
diffusely positive and intensely stained occasional tumor spindle cells. (I) Much of the tumor was also CD34-immunopositive. (J)
Scattered NeuN-immunopositive tumor cells were noted. (K) Epithelial membrane antigen immunostain yielded negative results.
(L) The Ki-67 labeling index was focally up to 35%. (M) A few nests of meningothelial cells were entrapped by tumor near the brain
pial surface. (N) Tumor extended into the Virchow-Robin space, eliciting astrogliosis. (O) Tumor cells in the Virchow-Robin space
demonstrated a gemistocyte-like or epithelioid morphology, including rare rhabdoid-like forms. Individual tumor cells invade the
neuropil. Original magnification: (A) 200, (B) 400, (C) 600, (inset 600x), (D) 400, (E) 100 (inset: 200), (F) 200, (G)
200, (H) 100, (I) 200, (J) 200, (K) 200, (L) 400, (M) 200, (N) 200, (O) 400.
© 2015 American Association of Neuropathologists, Inc.
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EGBs (Figs. 5A–C). The spinal biopsy revealed a tumor composed mostly of smaller, less pleomorphic cells enveloping and
invading the spinal roots (Fig. 5D). The deep intracerebral portion of the final intracranial recurrence retained immunoreactivity for S100 protein, Olig2, and GFAP, but the superficial
extra-axial portion did not. The Ki-67 labeling index of the latter
reached up to 50%.
Mutational analysis of the original resection specimen
for BRAFV600E yielded positive results. Tumor DNA was also
analyzed by next-generation sequencing (Foundation One,
Cambridge, MA), which confirmed the BRAFV600E mutation
and also revealed a TERT (telomerase reverse transcription) promoter −146C→T mutation and loss of CDKN2A/B.

DISCUSSION
Tumors reported to be neuroimaging mimics of meningiomas include hemangiopericytomas, solitary fibrous tumors,

schwannomas, hematolymphoid lesions, metastases, and others
(6–10). Very rarely, PXA (or so-called rare primary meningeal
gliomas) also may clinically mimic meningiomas (11–15).
Most primary meningeal gliomas were characterized as
Grade II to Grade IV astrocytomas (10, 13, 15–23); none was
diagnosed as PXA. Supratentorial examples were often close
to the lateral fissure (24), although examples have been reported
throughout the neuraxis, including those in the posterior fossa
near the tentorium (13, 16, 25–27). Of note, because PXA was
not defined until 1979, examples of PXA were likely considered
to be astrocytoma variants or glioblastoma before that date (1).
The histologic hallmarks of PXA include pleomorphism
manifested by variably small to medium neoplastic astrocytes
and large binucleated or multinucleated giant cells frequently
displaying nuclear vacuolation and/or prominent nucleoli. Their
tumor cells are immunoreactive for S100 protein and GFAP
(4). Pleomorphic xanthoastrocytoma, along with pilocytic astrocytoma and ganglioglioma, is also classically described

FIGURE 5. Case 2 recurrences. (A) Intracranial recurrence showing typical PXA histology. (B) Highly eosinophilic granular bodies
(center) are conspicuous. (C) An unusually large binucleated xanthomatous cell containing eosinophilic granular material. (D)
Tumor encasing and infiltrating spinal roots of the cauda equina. Original magnification: (A) 200, (B) 600, (C) 600, (D) 400.
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as containing EGBs. However, EGBs may be pale, sparse,
or absent, particularly in PXAs with anaplastic features (4).
Xanthomatous cells are also considered to be a characteristic
feature but may also be difficult to identify in some cases.
Lastly, pericellular reticulin deposition and immunoreactivity
for neuronal markers and CD34 are also classically described.
In practice, however, it is not uncommon for one or more of
these features to be absent in individual examples of PXA. More
recently, the V600E activating mutation of the BRAF serine/
threonine kinase has been identified in up to 66% of PXAs,
making PXA the most common CNS tumor showing this mutation (28–31).
Meningiomas, including recurrent meningiomas, have
been found to be BRAFV600E-negative in 3 large series (28, 32, 33).
Rhabdoid and other unusual meningiomas have rarely been reported to express GFAP by immunohistochemistry (34–36).
One case of recurrent rhabdoid meningioma with BRAFV600E
mutation has been reported; however, the report showed only
a single nondefinitive photomicrograph of the tumor (36). Notably, Mordechai et al (36) stated that PXA was also on their
differential diagnosis. Occasional S100 protein expression in
meningiomas is generally only weak or focal, not strong and
diffuse (37). In addition to oligodendrogliomas, Olig2 nuclear
positivity is common in astrocytomas but has not been reported in meningiomas (38–40). Most meningiomas are EMAimmunoreactive. Malignant meningiomas may have decreased
expression of EMA (37), but we did not see convincing EMA
immunopositivity even in the less pleomorphic meningiomalike areas in the cases reported here. Positive reticulin staining
highlighting the basal lamina between individual cells is also
typical of PXA but not meningioma (4). Notably, meningiomas
may demonstrate variable intercellular reticulin staining, but
stained fibers usually do not surround individual cells. Thus,
the cases presented herein are not consistent with meningioma.
CDNK2A/B loss has been reported in up to 46% of anaplastic meningiomas (41) and in up to 60% of PXAs (42). Similarly, TERT promoter mutation has also been reported in both,
albeit in a slightly lower percentage of anaplastic PXAs (23%)
(29) compared with meningiomas exhibiting progression (28%)
(43); however, it was much lower (3%) in meningiomas not
showing progression.

Common Features of the 2 Cases
Both cases presented primarily as extra-axial tumors in
adult women. Both showed only rare xanthomatous cells and
lacked conspicuous EGBs on initial resection but were otherwise consistent with PXA (i.e. exhibiting bizarre multinucleated
giant cells, glial differentiation, focal neuronal differentiation,
and reticulin). However, they lacked microvascular proliferation
and necrosis, thereby distinguishing them from giant cell and
epithelioid glioblastomas. The latter features may, however, be
observed in some—particularly recurrent—cases of PXA with
anaplastic features (4). Interestingly, as many as 2% to 3% of
glioblastomas overall (mostly pediatric or secondary glioblastomas) and as many as 7% to 11% of giant cell glioblastomas have
been reported to show the BRAFV600E mutation (28, 31). Giant
cell glioblastomas may be also differentiated from PXA by a relative lack of immunoreactivity for neuronal antigens (44).
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Both cases also demonstrated large areas of only mildly
pleomorphic meningothelial-like spindle cells with bland oval
nuclei suggestive of meningioma, and both showed fascicular
growth patterns. A single well-developed psammoma body was
noted in each case; this was within an isolated meningothelial
nest near the surface of the brain in Case 2 (Fig. 4M). Such
entrapped reactive meningothelial cells may be a diagnostic pitfall that could lead pathologists to confuse primary meningeal
PXAs with meningiomas. Cases 1 and 2 were similarly highly
proliferative, displaying 12 to 15 mitoses per 10 high-power
fields and Ki-67 labeling indices of up to 20% to 33% at presentation, respectively. Both also invaded the adjacent brain and recurred within 4 to 5 months of resection.
Eosinophilic granular bodies and large xanthomatous cells
may reflect phagocytosis of brain cellular components and
lipids, possibly explaining the less frequent occurrence of these
features in the original resection specimens of these primarily
extra-axial tumors. Indeed, xanthomatous cells were principally
found in areas adjacent to or within superficial brain tissue. An
entirely classic PXA histology was only seen after resection of
the extra-axial tumor and development of intra-axial tumor in
Case 2 (Figs. 5A–C). It is therefore possible that previous cases
diagnosed more generically as “meningeal glioma” or GFAPpositive meningioma could in fact have been PXAs but
were not recognized as such because of a lack of EGBs and
xanthomatous cells.
Pleomorphic xanthoastrocytomas frequently involve the
meninges, but examples occurring in a primary meningeal
extra-axial location without a radiologically distinct intra-axial
component are rare and not well documented. There is controversy on the histologic grading of PXAs with anaplastic features
because some patients, despite early recurrence, may have a relatively long survival (as in Case 1), whereas others experience a
relatively rapid progression and do very poorly (as in Case 2).
Histologic features that have been suggested to be associated
with poor survival include high mitotic rate, necrosis, and
rhabdoid cells (4, 45). Notably, Case 2 showed a higher mitotic
index but only focal rhabdoid-like cells. CDKN2A/B loss might
also have been an important factor, as it has been shown to be
associated with poorer survival in Grade II to Grade III diffuse
astrocytomas (46). Additional larger studies are needed to establish reliable histopathologic or molecular criteria to predict
World Health Organization Grade III behavior in PXA.
The extra-axial presentation of these tumors may provide
a clue to the origin of PXAs. Kepes et al (1) originally postulated that PXAs could be derived from subpial astrocytes. An
analogous hypothesis extrapolated to contemporary tumor stem
cell theory would implicate cortical radial glial or cortical or
leptomeningeal pluripotent neural progenitor cells derived from
radial glia or neural crest cells in the development of PXAs
(4, 47, 48).
In summary, we presented 2 cases of primary meningeal
PXA with anaplastic features and aggressive clinical courses.
One of these cases harbored a BRAFV600E mutation and—like
another recently reported case of progressive PXA with anaplastic features—showed clinical response to a targeted BRAF inhibitor: dabrafenib here and vemurafenib in the previously
reported case (49). The cases presented herein expand the differential diagnosis of dura-based tumors mimicking meningioma
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and underscore the need for careful histopathologic and molecular characterization (especially BRAF mutation analysis) in
histologically atypical and/or clinically aggressive meningeal
lesions, particularly those showing possible glial differentiation (i.e., S100 protein, GFAP, or Olig2 immunoreactivity).
Such testing may identify patients who could potentially benefit
from anti-BRAF targeted therapy.
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